BCRX
Price
$8.17
Change
+$0.05 (+0.62%)
Updated
Oct 2 closing price
Capitalization
2.16B
33 days until earnings call
Intraday BUY SELL Signals
NBIX
Price
$143.18
Change
+$2.47 (+1.76%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
14.27B
32 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCRX vs NBIX

BCRX vs NBIX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BCRX vs. NBIX commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a StrongBuy and NBIX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BCRX vs NBIX: Fundamental Ratings
BCRX
NBIX
OUTLOOK RATING
1..100
6273
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
10059
SMR RATING
1..100
10044
PRICE GROWTH RATING
1..100
6259
P/E GROWTH RATING
1..100
3391
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (16) in the Biotechnology industry is somewhat better than the same rating for NBIX (57). This means that BCRX’s stock grew somewhat faster than NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for BCRX (100). This means that NBIX’s stock grew somewhat faster than BCRX’s over the last 12 months.

NBIX's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for BCRX (100). This means that NBIX’s stock grew somewhat faster than BCRX’s over the last 12 months.

NBIX's Price Growth Rating (59) in the Biotechnology industry is in the same range as BCRX (62). This means that NBIX’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's P/E Growth Rating (33) in the Biotechnology industry is somewhat better than the same rating for NBIX (91). This means that BCRX’s stock grew somewhat faster than NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXNBIX
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
58%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
58%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
56%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 23 days ago
71%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 8 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
59%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
52%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (BCRX: $8.12 vs. NBIX: $140.71)
Brand notoriety: BCRX: Notable vs. NBIX: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BCRX: 131% vs. NBIX: 158%
Market capitalization -- BCRX: $2.16B vs. NBIX: $14.27B
BCRX [@Pharmaceuticals: Generic] is valued at $2.16B. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.27B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 2 FA rating(s) are green while NBIX’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 2 green, 3 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 6 bearish.
  • NBIX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а -4.69% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +1.27% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.71%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +29.84%.

Reported Earning Dates

BCRX is expected to report earnings on Nov 04, 2026.

NBIX is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.71% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
BCRX
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FTKI19.270.11
+0.58%
First Trust Small Cap Buywrite Income ETF
DIEM42.860.11
+0.26%
Franklin Emerging Market Core Dividend Tilt Index ETF (DIEM)
TXBC18.63N/A
N/A
21Shares FTSE Crypto 10 ex-BTC Index ETF (TXBC)
HPF13.46-0.01
-0.07%
John Hancock Preferred Income Fund II
PIEQ35.78-0.23
-0.63%
Principal International Equity ETF

NBIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with BIOA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then BIOA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-0.80%
BIOA - NBIX
37%
Loosely correlated
-3.95%
AKBA - NBIX
32%
Poorly correlated
-5.33%
ALKS - NBIX
31%
Poorly correlated
+0.05%
KNSA - NBIX
28%
Poorly correlated
+0.82%
BCRX - NBIX
26%
Poorly correlated
-2.52%
More